216 related articles for article (PubMed ID: 36464271)
1. Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study.
Ueba Y; Yamauchi I; Hakata T; Fujita H; Okamoto K; Ikeda K; Ueda Y; Fujii T; Taura D; Inagaki N
Endocr J; 2023 Mar; 70(3):323-332. PubMed ID: 36464271
[TBL] [Abstract][Full Text] [Related]
2. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
3. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
4. Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland.
Yamauchi I; Hakata T; Sugawa T; Kosugi D; Fujita H; Okamoto K; Ueda Y; Fujii T; Taura D; Harada N; Inagaki N
Endocr J; 2023 Oct; 70(10):987-998. PubMed ID: 37574279
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
6. Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events.
Muir CA; Wood CCG; Clifton-Bligh RJ; Long GV; Scolyer RA; Carlino MS; Menzies AM; Tsang VHM
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1843-e1849. PubMed ID: 35104870
[TBL] [Abstract][Full Text] [Related]
7. Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy.
Luongo C; Morra R; Gambale C; Porcelli T; Sessa F; Matano E; Damiano V; Klain M; Schlumberger M; Salvatore D
J Endocrinol Invest; 2021 Sep; 44(9):1927-1933. PubMed ID: 33576954
[TBL] [Abstract][Full Text] [Related]
8. [The association between baseline TPOAb and/or TgAb positivity and thyroid immune-related adverse events in patients with malignancies following treatment with immune checkpoint inhibitors].
Gao Y; Ye T; Wu LG; Xu Y; Wang X; Cheng XQ; Zhang YL; Wang YY; Fan XR; Zhao HT; Liu H; Chai XF; Zhang L; Wang MZ; Li NS; Lian XL
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(12):963-969. PubMed ID: 38514346
[No Abstract] [Full Text] [Related]
9. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
10. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
11. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
12. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018.
Molina GE; Zubiri L; Cohen JV; Durbin SM; Petrillo L; Allen IM; Murciano-Goroff YR; Dougan M; Thomas MF; Faje AT; Rengarajan M; Guidon AC; Chen ST; Okin D; Medoff BD; Nasrallah M; Kohler MJ; Schoenfeld SR; Karp Leaf RS; Sise ME; Neilan TG; Zlotoff DA; Farmer JR; Mooradian MJ; Bardia A; Mai M; Sullivan RJ; Semenov YR; Villani AC; Reynolds KL
Oncologist; 2021 Jun; 26(6):514-522. PubMed ID: 33655682
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review.
Yoo WS; Ku EJ; Lee EK; Ahn HY
Endocrinol Metab (Seoul); 2023 Dec; 38(6):750-759. PubMed ID: 37956967
[TBL] [Abstract][Full Text] [Related]
14. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
[TBL] [Abstract][Full Text] [Related]
16. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
[TBL] [Abstract][Full Text] [Related]
17. Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy.
Yamaguchi A; Saito Y; Narumi K; Furugen A; Takekuma Y; Shinagawa N; Shimizu Y; Dosaka-Akita H; Sugawara M; Kobayashi M
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1659-1666. PubMed ID: 36346501
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Timing of Immune-Related Adverse Events in Immune-Checkpoint Inhibitor-Treated Patients: A Retrospective Observational Study.
Masaki K; Miyazaki M; Kakimoto H; Fukiage Y; Fukue H; Nakashima A; Imakyure O
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137632
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects.
Iwamoto Y; Kimura T; Dan K; Ohnishi M; Takenouchi H; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
Front Endocrinol (Lausanne); 2023; 14():1221723. PubMed ID: 37583431
[TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
